LY517717

Known as: LY 517717, LY-517717 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2013
02420052013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… (More)
Is this relevant?
Review
2010
Review
2010
Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the… (More)
Is this relevant?
Review
2009
Review
2009
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… (More)
Is this relevant?
Review
2009
Review
2009
For the past five decades, there has been little progress in the development of oral anticoagulants, with the choices being… (More)
Is this relevant?
Review
2009
Review
2009
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and… (More)
Is this relevant?
2008
2008
(VTE) and in some countries for the treatment of acute coronary syndromes. Idraparinux, a subcutaneous, longacting, indirect… (More)
Is this relevant?
2007
2007
BACKGROUND LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development. OBJECTIVES… (More)
Is this relevant?
Review
2006
Review
2006
Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of… (More)
Is this relevant?
Review
2006
Review
2006
Novel anticoagulants to replace unfractionated heparins, low molecular weight heparins and vitamin K antagonists, are needed… (More)
Is this relevant?
Review
2005
Review
2005
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and… (More)
Is this relevant?